Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Pasic

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Annals of Hematology|March 12, 2021
Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantationArjun Datt Law, Sita Bhella, Ivan Pasic, et al.
Transplantation and Cellular Therapy|March 23, 2026
GVHD prophylaxis with ATG and PTCy versus PTCy-based regimens in haploidentical stem cell transplantation: A CTTC studyAlejandro Garcia-Horton, Brittany Salter, Kristjan Paulson, et al.
Transplantation and Cellular Therapy|August 15, 2023
Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation RecipientsAnkit Mittal, Javier T Solera, Victor H Ferreira, et al.
European Journal of Haematology|January 31, 2022
Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myelomaRam Vasudevan Nampoothiri, Ivan Pasic, Arjun Datt Law, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort StudyMatthew D Seftel, Ivan Pasic, Gaganvir Parmar, et al.
Transplantation and Cellular Therapy|June 13, 2025
Association of Cyclosporine Exposure Post-Allogeneic Hematopoietic Cell Transplant with Graft Failure and Relapse Risk in Hematological MalignanciesAhmed Alnughmush, Mats Remberger, Vathany Kulasingam, et al.
British Journal of Haematology|September 18, 2025
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxisRuah Alyamany, Ahmed Alnughmush, Mats Remberger, et al.
European Journal of Haematology|May 29, 2025
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD ProphylaxisAhmed Alnughmush, Ruah Alyamany, Mats Remberger, et al.
Hematology/Oncology and Stem Cell Therapy|August 15, 2023
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment OutcomesSwe M Linn, Igor Novitzky-Basso, Omar Abduljalil, et al.
Transplantation and Cellular Therapy|January 22, 2026
Frailty as a prognostic factor in younger adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationSergio Rodriguez-Rodriguez, Maria Queralt Salas, Nihar Desai, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Annals of Hematology|March 12, 2021
Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantationArjun Datt Law, Sita Bhella, Ivan Pasic, et al.
Transplantation and Cellular Therapy|March 23, 2026
GVHD prophylaxis with ATG and PTCy versus PTCy-based regimens in haploidentical stem cell transplantation: A CTTC studyAlejandro Garcia-Horton, Brittany Salter, Kristjan Paulson, et al.
Transplantation and Cellular Therapy|August 15, 2023
Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation RecipientsAnkit Mittal, Javier T Solera, Victor H Ferreira, et al.
European Journal of Haematology|January 31, 2022
Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myelomaRam Vasudevan Nampoothiri, Ivan Pasic, Arjun Datt Law, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort StudyMatthew D Seftel, Ivan Pasic, Gaganvir Parmar, et al.
Transplantation and Cellular Therapy|June 13, 2025
Association of Cyclosporine Exposure Post-Allogeneic Hematopoietic Cell Transplant with Graft Failure and Relapse Risk in Hematological MalignanciesAhmed Alnughmush, Mats Remberger, Vathany Kulasingam, et al.
British Journal of Haematology|September 18, 2025
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxisRuah Alyamany, Ahmed Alnughmush, Mats Remberger, et al.
European Journal of Haematology|May 29, 2025
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD ProphylaxisAhmed Alnughmush, Ruah Alyamany, Mats Remberger, et al.
Hematology/Oncology and Stem Cell Therapy|August 15, 2023
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment OutcomesSwe M Linn, Igor Novitzky-Basso, Omar Abduljalil, et al.
Transplantation and Cellular Therapy|January 22, 2026
Frailty as a prognostic factor in younger adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationSergio Rodriguez-Rodriguez, Maria Queralt Salas, Nihar Desai, et al.
Pageof 10